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Recombinant human tissue-type plasminogen activator
(rt-PA), a relatively dot-specific fibrinolytic agent, rep-
resents a novel and promising approach to thrombolytic
therapy of pulmonary embolism. Therefore, the efficacy
and safety of peripheral intravenous rt-PA therapy were
assessed in 47 patients with angiographically docu-
mented pulmonary embolism. The drug regimen was 50
mg over 2 hours followed by repeat angiography and,
if necessary, an additional 40 mg over 4 hours. By 6
hours, 44 of the 47 patients had angiographic evidence
of clot lysis that was slight (n = 5), moderate (n = 12)
or marked (n = 27). Among the 34 patients with pul-
monary hypertension before treatment (mean pulmn-
Although the Food and Drug Administration (FDA) ap-
proved thrombolytic therapy for acute pulmonary embo-
lism in 1977, clinicians rarely employ this treatment. De-
spite a strong endorsement by a consensus development
conference of the National Institutes of Health in 1980 (l ),
currently available lytic agents are viewed as having myriad
disadvantages compared with standard heparin anticoagu-
lation. From a pragmatic viewpoint, the treating physician
who chooses thrombolysis as initial therapy must be pre-
pared to devote a great deal of additional effort to the pa-
tient's management. Such a physician should anticipate in-
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nary artery pressure exceeding 17 mm Hg), the pressure
decreased from 43/17 (mean 27) to 31/13 (mean 19) mm
Hg (p < 0.0001).
Fibrinogen decreased 33% from baseline at 2 hours
and 42% from baseline at 6 hours. There were two major
complications that required surgical control of bleeding:
hemorrhage from a pelvic tumor and mediastinal tam-
ponade in a patient 8 days after coronary artery bypass
surgery. The initial results demonstrate that, among se-
lected patients, peripheral intravenous rt-PA can rapidly
and, for the most part, safely lyse pulmonary embolism
within 6 hours.
(J Am Coli CardiolI987;IO:96B-104B)
creased morbidity from bleeding. queries from nursing staff
about how to monitor the patient clinically. inquiries from
the hospital pharmacy about the dosage and drug reconsti-
tution procedures, uncertainty about the optimal protocol
for laboratory monitoring and increased costs of an expen-
sive drug (for example, urokinase, streptokinase or tissue
plasminogen activator) compared with inexpensive heparin.
These disadvantages of thrombolysis are immediately evi-
dent whereas the potential advantages to this strategy are
hidden. Thrombolysis may prevent chronic pulmonary hy-
pertension, reduce the frequency of recurrent pulmonary
embolism and reduce the mortality rate, However, these
benefits remain theoretical because they have not been dem-
onstrated in randomized trials of thrombolysis followed by
heparin anticoagulation compared with anticoagulation alone.
Whereas the diffidence of nursing, pharmacy and laboratory
staff can be altered by improved educational efforts, the
increased bleeding and cost of lytic agents must be ac-
knowledged as barriers that justifiably cause many clinicians
to utilize thrombolysis only rarely.
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Table 1. Experience With t-PA in Experimental Venous Thromboembolism
Animal ~lodel Drugs Compared Results
Canine superficial femoral venous
thrombosis (5 )
Rabbit jugular venous thrombosis (o j
Rabbit jugular venous thrombosis (7 )
Rabbit pulmonary embolism ( ~)
I mg t-PA vs. I million n; UK
\ mg t-PA vs. SOO.OOO IU UK
0. 15 mg/kg per h x 4 hours
t-PA vs. I(i.OOO units/kg per
h x 4 hours SK
0 .35 mg t-PA vs. 1.000.000 lJK
SOCk more lysis with t-PA
SOCk more lysis with l-PA
49% more lysis wit h t-PA
330/c more lysis with l-PA
I-PA = tissue-type plasminngen activator: SK = streptokinase: UK = urokinase.
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Figure 2. Effect in pulmonary artery (PA) pressure. A, Average
pressure in 47 patients decreased from 38/15 (mean 23) to 29112
(mean 18) mm Hg. B, Among the 34 patients with pulmonary
hypertension before treatment (that is. mean pulmonary artery
pressure > 17 mm Hg), the pressure decreased from 43/ 17 (mean
27) to 3 1/ 13 (mean 19) mrn Hg.
50
hour treatment course of urokinase is cumbersome and ex-
pensive. For example, an 80 kg patient would require ap-
proximately 4.6 million LJ : this would necessitate reconsti-
tution of 19 vials of drug (250,000 Urvial) and would cost
the hospital pharmacy approximately $3,100.
Only three randomized trials (2-4) have compared
thrombolytic therapy of pulmonary embolism with heparin
anticoagulation and comprise a total of only 2 10 patients.
The Urokinase Pulmonary Embolism Trial (UPET) of 160
patients (2) was the single largest study to examine this
First Generation Thrombolytic Agents
Urokinase appears to be superior to streptokinase because
of a much lower rate of allergic reactions (such as fever,
chills or fl ushing) and the ability to administer the agent on
repeated occasions without inducing an antibody response
that causes drug resistance. Urokinase is also more fibrin
specific than streptokinase. However. the recommended 12
150 mg rt-PA via pe ripheral IV I
I
2 hours
J.IPAgram repeated I
j \
I-S-,-gn-I-nc-a-n-t-c-lo-t-l-y-sl-sI I"":'N7"o--:si-gn"":'II:::'"'c-a-n':'"t-c7"lo"':'"t"":'ly-s"':'"is-1
.. -:-::::-:----:-~..~-...,......,:-::-lIStUdy termlnat es· l ~ddltlonal 40 mg rt-PA I
I
4 hours
..IPAgram repeated I
+IStudy terminates. I
Figure L The study protocol for recombinant tissue-type plas-
minogen activator (rt-PA) in the treatment of acute pulmonary
embolism. IV = intravenous; PAgram = pulmonary angiogram.
What are the ideal attributes of a therapeutic agent to
treat pulmonary embolism? First and foremost, the drug
needs to be administered safely and easily, with minimal
laboratory monitoring and dose adjustment. Second, im-
mediate evidence of efficacy should be apparent by utilizing
any variable that one wishes to follow: reduction in pul-
monary artery pressures, clot lysis as assessed by follow-
up pulmonary angiogram or lung scan, or improved right
heart function as imaged on Doppler echocardiogram. Third,
convincing clinical trials should exist to prove that a par-
ticular strategy eliminates the source of the pulmonary em-
bolism. prevents pulmonary embolism recurrence, reduces
mortality and prevents the dreaded long-term complication
of pulmonary hypertension. Currently available thrombo-
lytic agents have been only partially successful in meeting
these objectives.
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issue. and its results were inconclusive. After 24 hours of
treatment, there was markedly greater resolution of hemo-
dynamic abnormalities, angiographic filling defects and lung
scan perfusion defects among those patients who received
urokinase compared with the heparin-treated group. How-
ever, I week after initiation of therapy, no significant dif-
ferences could be detected between the two groups. Fur-
thermore, major bleeding complications, defined as a
hematocrit drop of more than lO points or a transfusion
requirement of more than 2 units, occurred twice as fre-
quently among patients who received urokinase.
Tissue Plasminogen Activator (t-PA)
The development of tissue plasminogen activator produced
by recombinant techniques (rt-PA), a second generation
thrombolytic agent with relative fibrin specificity, has led
to reexaminationof the roleof lytic therapy in venous throm-
buembolism. Experimental studies in animal models (5- 8)
indicated that t-PA was more potent than urokinaseor strep-
tokinase and possibly safer (Table I) . Initial case reports in
patients also proved promising (9,10) .
An important issue to address initially is whether therapy
with this second generation fibrinolytic agent appears effi-
Figure 3. Right anterior oblique right pulmonary angiograms in
a 43 yearold woman with pulmonary embolism. A, A large em-
bolus in the right pulmonary artery (arrow). B, After 2 hours of
rt-PA therapy, there is marked improvement, with only a small
amount of residual thrombus in peripheral branches. (Reprinted
with permission from Goldhaber er al. [11 J.)
cacious and safe for patients with pulmonary embolism.
Therefore, we carried out an open label study in which we
administered open label rt-PA to 47 patients with angio-
graphically documented acute pulmonary embolism. Our
objective was to evaluate the short-term efficacy and safety
of rt-PA rather than the possible long-term benefit of the
drug. We have previously described the complete results in
36 patients and the preliminary results in an additional seven
(11,12). After 2 to 6 hours of therapy, 44 of 47 patients
demonstrated significant clot lysis on repeat pulmonary an-
giograms and 45 of 47 experienced no major bleeding com-
plications.
The study group included adults with angiographically
documented pulmonary embolism in a segmental or more
proximal pulmonary artery; the exclusion criteria were sim-
ilar to those of the Urokinase Pulmonary Embolism Trial
(UPET). We infused 50 mg of rt-PA (Activase, supplied
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Figure 4. Anteroposterior right pulmonary angiograms in a 66 year
old man with pulmonary embolism. A, Emboli in the right upper pul-
monary lobe, right middle lobe and right lower lobe \drrows). B, After
2 hours of rt-PA therapy, there is partial resolution in the anterior and
posterior segments of the right upper lobe but complete occlusion of
the branch supplying the apical segment. There is partial resolution of
the emboli in the right lower lobe. C, After 6 hours of rt-PA. there
has been almost complete resolution of emboli in all segments of the
right lung.
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Figure S. Right posterior oblique right pulmonary angiograms in a 30
year old man with pulmonary embolism. A, A large embolus occluding
the right lower lobe distal to the superior segmental artery (arrow). B,
After 2 hours of rt-PA therapy, there is partial resolution with reperfusion
of the anterior basal, medial basal and lateral basal segments. C, After
6 hours of rt-PA, there has been complete resolution of the emboli.
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Figure 6. Anteroposterior right pulmonary angiograms in a 48 year
old woman with pulmonary embolism. A, A large embolus in the main
right pulmonary artery causing complete occlusion of the right upper
lobe branch and partial occlusion of the right middle and right lower
lobe branches (arrows). B, After 2 hours of rt-Pa therapy, there has
been resolution of the embolus in the main right pulmonary artery, but
there are emboli still present more distally (arrows), C, After 6 hours
of rt-PA, there has been marked further resolution of the emboli in the
right middle and right lower lobe branches. There has also been a
decrease in the size of the embolus in the right upper lobe branch,
although this has not cleared completely (arrow).
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Figure 7. Anterior and posterior views of perfusion lung scans in
a 66 yearold man whopresented with syncope. Top panel, Before
recombinant tissue-type plasminogen activator (rt-PA) therapy the
scans show massive pulmonary embolism. Except for a region in
the midportion of the right lung, there is marked reduction and
irregularity of perfusion in both lung fields. Lower panel, A lung
scan performed 1 day after therapy with 90 mg of rt-PA shows
nearly complete resolution of the defects. The only remaining
perfusion defect is at the left base on the posterior view. ANT ==
anterior; POST = posterior. (Figure kindly provided byJ. Anthony
Parker. MD. PhD. and reprinted with permission from Goldhaber
SZ, Braunwald E. Tissue plasminogen activators in the treatment
of acute pulmonary embolism. In: Sobel BE. Collen D. Grossbard
EB.eds. Tissue Plasminogen Activators. New York: Marcel Dek-
ker. 1987:147-69.)
POSTANT
surgery, had mediastinal tamponade and required emer-
gency bedside mediastinal exploration. yielding 500 ml of
bloody fluid. In the majority of patients there was superficial
skin oozing from venipuncture or arterial puncture sites,
readily controlled with manual pressure and pressure dress-
ings. Other minor and transient bleeding complications were
hematuria in three patients and periodontal oozing in three
patients with periodontal disease. The development of a
groin hematoma usually correlated with failure to cannulate
the femoral vein percutaneously on the first attempt, and in
seven patients precluded administration of an intended full
90 mg dose.
rt-PA versus urokinase. Any historical comparison be-
tween our rt-PA study and the urokinase trial (UPET) must
be undertaken with extreme caution, even though the panel
of physicians that assessed the rt-PA angiograms used the
criteria developed by UPET investigators. After 2 or 6 hours
of rt-PA treatment, the panel judged that 83% of our patients
showed moderate or marked improvement. compared with
by Genentech, Inc.) through a peripheral vein over 2 hours
(25 mg/h) (Fig. I) and repeated the angiogram immediately
thereafter. If this showed clot lysis, the study was termi-
nated; if no clot lysis had occurred, an additional 40 mg of
rt-PA was administered (unless precluded by bleeding com-
plications) over the ensuing 4 hours (10 mg/h) and angi-
ography was repeated. Administration of heparin was usu-
ally stopped several hours before diagnostic angiography;
in all instances, it was discontinued before rt·PA adminis-
tration.
Utilizing blinded consensus reading (without knowledge
of whether a particular angiogram was obtained before or
after treatment), a panel of investigators assessed the an-
giograms. In judging qualitative changes, the panelists re-
lied on their overall subjective impression of whether there
was marked, moderate, slight or no change between blinded
sets of angiograms from each patient.
Baseline and posttreatment characteristics. Of the 47
patients, 37 were medical and 10 were postoperative. The
mean preinfusion hemodynamic variables (in mm Hg) were:
right atrial pressure 8, right ventricular pressure 34/8; pul-
monary artery pressure 38/15 (mean 22) and systemic ar-
terial pressure 123/76. Average pulmonary artery pressures
decreased after rt-PA therapy (Fig. 2), but none of the other
pressures changed significantly. Of the 47 patients, 19 re-
ceived rt-PA for just 2 hours and 28 received rt-PA for 6
hours. Afterward, patients reverted to the care of the primary
hospital physicians, most of whom resumed heparin therapy
when the thrombin time or partial thromboplastin time was
about twice the control value.
Assessment of clot lysis. Qualitatively, 44 of the 47
patients had angiographic evidence of clot lysis after treat-
ment with rt-PA. When improvement occurred, it was slight
in II %. moderate in 27% and marked in 62% (Fig. 3 to
6). Whereas serial unilateral pulmonary angiography pro-
vides an excellent demonstration of the changes within the
vasculature of one lung. lung scanning provides direct in-
formation about the perfusion of both lungs. A subset of
our patients underwent perfusion lung scanning before and
after rt-PA treatment. Initially, an average of 35% of the
pulmonary tissue lacked perfusion. One day after rt-PA
therapy, only 15% of the pulmonary tissue was not perfused
(Fig. 7) (13). Before treatment, Doppler echocardiography
in some patients documented right ventricular failure, man-
ifested by right ventricular dilation and tricuspid regurgi-
tation. This resolved rapidly after rt-PA therapy (14). On
average, the right ventricular diameter decreased from 3.9
to 2.2 em. Plasma fibrinogen decreased from 356 mg/dl
before treatment to 239 mg/dl at 2 hours and 208 mg/dl at
6 hours.
Complications of therapy. Two patients had a major
hemorrhagic complication. One bled from a pelvic tumor
and required a laparotomy. The other, treated with 50 mg
of rt-PA on the eighth day after coronary artery bypass
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Table 2. Ideal Attributes of Thrombolytic Agents in Treatment of Pulmonary Embolism
Attribute
Safe ty
Ease of adminixtration
Minimal laboratory monitoring/dose
adjustment
Low cost
Immediate evidence or efficacy
Decreased PA pressures
Improved pulmonary angiogram
Improved lung scan
Improved Doppler echocardiogram
Long-term efficacy convincingly
documented in a well executed
clinical trial
Eliminates source of PE
Prevents PE recurrence
Reduces mortality
Prevents pulmonary hypertension
Current Status
Yes, in -ciectcd patients
UK. cumbersome: rr-PA,
each vial contains / :
to I entire dose
Yes (hut not widely
appreciated )
No
Yes
Yes
Yes
Yes (with n-PA)
No
No
No
No
Future Potential
improvement with new agents
Dr with synergism of
currently available agents
Streamline procedures for
drug reconst itution and
administration
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
PA = pulmonary artery: PE = pulmonary embolism: other abbrevia tums as in Table l ,
42% of the patients who received urokinase for 24 hours in
the UPET. Similarly, 24 hours after treatment was started.
lung scan perfusion improved 57% with rt-PA, compared
with a 24% improvement after urokinase. These data arc
useful for generating the hypothesis that rt-PA is a more
potent lytic agent than is urokinase. However, the physicians
who assessed the angiograms in the UPET were. of course,
different from the physicians in our study. and the two
patient groups may not have been comparable.
The rate of major bleeding complications was lower in
rt-PA-treated patients than in those who received urokinase
in the UPET. This difference in bleeding may simply be
ascribed to improved clinical skill in managing patients who
are receiving lytic therapy. Alternatively. it is possible that
rt-PA is safer than urokinase.
Ongoing studies ofrt-PA in pulmonary embolism. On
the basis of our promising results with open label rt-PA.
we have embarked on a trial in which patients with pul-
monary embolism are randomized to either 100 mg of rt-
PA or to urokinase, each given over 2 hours. This trial will
permit us to compare the efficacy and safety of urokinase
(that is, standard thrombolytic therapy for pulmonary em-
bolism) with short course, high dose rt-PA. We will also
learn whether a 2 hour treatment with urokinase is effective.
Three other groups of investigators are studying rt-PA treat-
ment in pulmonary embolism. Members of the Prospective
Investigation of Pulmonary Embolism Diagnosis (PIOPED)
research group have piloted a randomized trial in which
heparin plus 40 mg of rt-PA is compared with standard
heparin therapy. An international multicenter study in Eu-
rope has been comparing peripheral intravenous versus local
intrapulmonary administration of rt-PA and has observed
no difference in effi cacy or safety ( 15). Another approach,
. 'burst therapy." isbeing investigated in Hamilton, Ontario,
Canada. Eligible patients are receiving 0.6 mgikg of rt-PA
over 2 minutes ( 16) .
Future Potential of Lytic Therapy
If well executed clinical trials demonstrate that throm-
bolytic therapy reduces morbidity and mortality of pulmo-
nary embolism compared with heparin anticoagulation, then
the future potential of lytic therapy may be fully realized
(Table 2) . One can envision future management that max-
imizes accurate diagnosis followed by expeditious and safe
treatment.
Using the analogy of suspected myocardial infarction.
the lung scan for suspected pulmonary embolism can be
considered a screening test similar to the electrocardiogram.
Just as thrombolytic therapy is currently administered to
patients with suspected (but not angiographically confirmed)
myocardial infarction. lytic treatment of pulmonary em-
bolism could be justified in circumstances in which the
probability of pulmonary embolism is high but not defini-
tively proved with angiography. Willingness to administer
thrombolytic agents to patients with a high probability of
pulmonary embolism would etiminate the single most fre-
quent source of drug morbidity: bleeding from the vascular
access site for the angiogram. Of course. patients with mod-
erate or indeterminate probability of pulmonary embolism
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and those with high clinical SUspicion of pulmonary em-
bolism despite low probability scans would still undergo
angiography. To monitor the efficacy of pulmonary em-
bolism treatment, perhaps the lytic agent could be radio-
labeled and used for lung scans. Serial lung scanning could
then readily document clot dissolution.
Improvements in the safety of lytic agents can also be
envisioned. One exciting approach is use of low doses of
two currently available agents that may possibly demon-
strate synergy (17,18). For example, Collen et 411. (19) re-
ported that three of four patients with acute myocardial,
infarction experienced lysis of coronary artery occlusion
with only 10 mg of rt-PA and 300,000 IV of urokinase. It
is intriguing, however, that Collen et 411. (20) did not detect
synergy when they studied these same two agents in vitro.
Summary
The clinical benefitof thrombolytic therapy in acute pul-
monary embolism is easiest to appreciate among patients
with massive pulmonary embolism. With rt-PA treatment,
mostof these patientsundergorapid reduction of abnormally
elevated right heart pressures, lysis of large pulmonary ar-
terial clots within 6 hours and consequent restoration of
normal right ventricular function. At this point, we need to
address a fundamental question about the role of throm-
bolytic therapy in the routine treatment of pulmonary em-
bolism. Does thrombolytic therapy reduce the frequency of
important end points such as mortality and recurrent pul-
monary embolism? As thrombolytic agents become em-
ployed more frequently in the treatment of cardiovascular
diseases, this issue with regard to pulmonary embolism is
timely. Our belief is that a cooperative multicenter trial
should study these end points by comparing thrombolytic
therapy with heparin anticoagulation for routine treatment
of patients with pulmonary embolism.
Appendix
Other participating investigators
Beth Israel Hospital. Patricia Come. MD; Gerard M. Kolodny. MD;
J. Anthony Parker, MD, PhD.
Brigham and Women's Hospital. B. Leonard Holman. MD; J. Stevan
Nagel, MD; Kathleen Reagan, MD; Sabah Tumeh, MD.
George Washington University Medical Center. Edward Druy, MD;
William xeuv, MD; K. Siena Kirwin. MD.
Veterans' Administration Medical Center at BrocktonlWest Rox-
bury. Daniel A. Pietro. MD.
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